Investigating the pharmacodynamic mechanism of Erxian decoction to alleviate sarcopenia generated by ovarian aging through the ER-mediated estrogen signaling pathway.

Fengming You, Ning Wang, Jiaojiao Yang, Yuxi Dong, Nian Liu, Piwen Zhao

School of Life Sciences, Beijing University of Chinese Medicine, No.11 East Road, North 3rd Ring Road, Beijing, 100029, China.School of Life Sciences, Beijing University of Chinese Medicine, No.11 East Road, North 3rd Ring Road, Beijing, 100029, China. · pubmed

Paper

Abstract

Erxian decoction (EXD) is widely used in the treatment of various gynecological conditions, including menopausal syndrome, ovarian insufficiency, and premature ovarian failure (POF). As society ages, the prevalence of postmenopausal osteoporosis (PMOP) rises annually, accompanied by a progressive increase in the incidence of sarcopenia, a skeletal muscle disorder associated with osteoporosis. Recent studies have revealed that the diverse pharmacological agents and active compounds in EXD have been utilized in clinical and experimental contexts for sarcopenia; nevertheless, the mechanism by which EXD addresses postmenopausal sarcopenia remains unclear.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that Erxian decoction alleviates sarcopenia caused by ovarian aging through the ER-mediated estrogen signaling pathway. The research addresses a specific aspect of aging-related conditions, particularly sarcopenia, which is linked to hormonal changes in postmenopausal women, thus contributing to the understanding of age-related muscle degeneration.

Author of this paper? Send a correction.